SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : YellowLegalPad
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: John McCarthy9/21/2010 9:22:52 PM
   of 1182
 
CYCC (1.56)

The clinical stage compounds in development include:

Sapacitabine,

which is designed to treat elderly patients with acute myeloid leukemia (AML) and myelodyspalstic syndromes (MDS);

seliciclib

for the treatment of non-small cell lung cancer (NSCLC) and nasopharyngeal cancer;

and CYC116,

designed to treat patients with solid tumors.

While there is promising data for selicibilib, which is currently in a phase 2 trial for NSCLC, I will focus on

Sapacitabine, the clear value driver which has potential to be a leader in a $2 billion market.

seekingalpha.com

CRACKER
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News